Via Telefax

2415F USA

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended). ~~The~~ A therapeutic method for the treatment of ~~the~~ a mammalian joint with ~~degeneration of the~~ articular cartilage exhibiting degeneration caused by osteoarthritis, ~~characterized by~~ comprising (i) the ~~performance of three applications~~ intraarticular implantation of a pharmaceutically effective ~~doses~~ amount of a viscoelastic composition comprising an aqueous vehicle with 40 ~~compound containing a proportion of 60~~ mg of chondroitin sulfate and ~~a proportion of 45~~ 30 mg of sodium hyaluronate per cubic centimeter of ~~viscoelastic solution, and/or a proportion of 30 mg of chondroitin sulfate and a proportion of 22.5 mg of sodium hyaluronate per cubic centimeter of~~ said vehicle ~~viscoelastic solution, and/or a proportion of 20 mg of chondroitin sulfate and a proportion of 15 mg of sodium hyaluronate per cubic centimeter of viscoelastic solution, following the standards of intraarticular infiltration, once every 15 days, and ii) the application of a reinforcement or maintenance dose every 3, 6, 9 or 12 months, according to the damage in the articular cartilage of the patient~~.

Via Telefax

2415F USA

Claim 2 (currently amended). The therapeutic method according to claim 1, wherein ~~in which~~ the mammalian joint is a human joint, the intraarticular implantation is effected with a hypodermic needle, and the articular cartilage ~~can be~~ is selected from the group ~~formed by~~ consisting of the following joints: i) knees, shoulders and sacroiliac; ii) coxofemoral, ankles and elbows; and iii) interphalangeal and wrists.

Claim 3 (currently amended). The therapeutic method according to claim 1, in which ~~each~~ the pharmaceutically effective ~~dose~~ amount ~~is~~ comprises 1.5 cubic centimeters of the ~~compound~~ composition according to claim 1 for ~~the~~ a joint selected from the group consisting of: knee, shoulder ~~or~~ and sacroiliac ~~joints~~.

Claim 4 (currently amended). The therapeutic method according to claim 1, in which ~~every~~ the pharmaceutically effective ~~dose~~ amount ~~is~~ comprises 0.75 cubic centimeters of the ~~compound~~ composition according to claim 1 for ~~the~~ a joint selected from the group consisting of: coxofemoral, ankle and elbow ~~joints~~.

Claim 5 (currently amended). The therapeutic method according to claim 1, in which ~~every~~ the pharmaceutically effective ~~dose~~ amount ~~is~~ comprises 0.5 cubic centimeters of the compound according to claim 1 for a joint selected from the group consisting of ~~the~~ interphalangeal and wrist ~~joints~~.

Via Telefax

2415F USA

Page 25, Paragraph beginning at line 4, please delete in its entirety.